Taraxasterol

Taraxasterol is a pentacyclic triterpenoid found primarily in dandelion (Taraxacum officinale) that exerts anti-inflammatory effects by suppressing pro-inflammatory cytokine production and inhibiting NF-κB signaling pathways. Current evidence is limited to in vitro and animal studies, with no human clinical trials yet validating its therapeutic potential.

Origin & History

Taraxasterol is a pentacyclic triterpenoid compound primarily isolated from Taraxacum officinale (dandelion), with the molecular formula C₃₀H₅₀O. It is extracted from plant sources using solvent extraction methods and is characterized by its complex pentacyclic ring structure typical of triterpenes.

Historical & Cultural Context

The research dossier does not provide information on taraxasterol's historical use in traditional medicine systems or the specific conditions it was traditionally used to treat. Additional sources would be needed to establish traditional medicine applications.

Health Benefits

• Anti-inflammatory properties (identified in multiple sources, though specific human clinical trials not provided)
• Potential therapeutic effects (based on in vitro biological activities, human evidence not available)
• Note: The research dossier lacks human clinical trials, RCTs, or meta-analyses to substantiate specific health benefits
• Further clinical research needed to establish efficacy
• Current evidence limited to laboratory characterization and theoretical mechanisms

How It Works

Taraxasterol inhibits the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling pathway, reducing transcription of pro-inflammatory genes including TNF-α, IL-1β, and IL-6. It also suppresses COX-2 (cyclooxygenase-2) expression and MAPK (mitogen-activated protein kinase) phosphorylation, dampening downstream inflammatory cascades. Additionally, taraxasterol has demonstrated inhibition of iNOS (inducible nitric oxide synthase), limiting nitric oxide-mediated oxidative stress in preclinical cell culture models.

Scientific Research

The research dossier explicitly states that no specific human clinical trials, randomized controlled trials, meta-analyses, or PubMed PMIDs evaluating taraxasterol's clinical efficacy were found. The available sources focus on chemical characterization and in vitro biological activities rather than clinical outcomes data.

Clinical Summary

All current evidence for taraxasterol derives from in vitro cell culture experiments and rodent animal models; no human randomized controlled trials, observational studies, or meta-analyses have been published as of 2024. Animal studies have demonstrated anti-inflammatory effects at doses ranging from 10–100 mg/kg body weight in murine models of arthritis and liver injury, though direct human dose extrapolation is not validated. In vitro studies show measurable reductions in IL-6 and TNF-α at concentrations of 10–80 μM, but achieving comparable tissue concentrations in humans through oral supplementation has not been established. The overall evidence strength is preclinical only, and any health claims for human use remain speculative without clinical trial data.

Nutritional Profile

Taraxasterol is a pentacyclic triterpene compound (molecular formula C30H50O, molecular weight ~426.72 g/mol), not a macronutrient or micronutrient in the conventional dietary sense. It is a bioactive phytosterol found primarily in Taraxacum officinale (dandelion) and related Asteraceae family plants. Concentration in dandelion root extract ranges approximately 0.01–0.1% of dry weight, with higher concentrations in root vs. leaf tissue. As a triterpene alcohol, it contains no protein, carbohydrate, or fiber content intrinsically. It is lipophilic in nature, meaning bioavailability is enhanced when consumed with dietary fats; aqueous solubility is low (<1 mg/mL). Absorption is presumed to follow passive diffusion pathways typical of triterpenoids, with first-pass hepatic metabolism likely reducing systemic bioavailability, though precise human pharmacokinetic data (Cmax, Tmax, half-life) are not yet established in published clinical literature. It co-occurs in plant sources alongside related triterpenes such as taraxerol, lupeol, and beta-amyrin. No caloric contribution is assigned in nutritional contexts. Standardized extracts in research settings typically use concentrations of 10–50 µg/mL for in vitro bioactivity assays.

Preparation & Dosage

No clinically studied dosage ranges or standardized extract concentrations were provided in the research. Laboratory solubility data shows taraxasterol dissolves in ethanol at 5.5 mg/mL and in DMSO at 1 mg/mL, but these are not clinical dosing recommendations. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other dandelion compounds, anti-inflammatory herbs, triterpenoids, pentacyclic compounds

Safety & Interactions

No formal human safety studies, toxicology trials, or established safe dosage ranges exist specifically for isolated taraxasterol supplementation. Individuals allergic to plants in the Asteraceae/Compositae family (ragweed, chrysanthemums, marigolds) should exercise caution, as taraxasterol is derived from dandelion, a member of this family. Theoretical interactions with anticoagulant drugs (e.g., warfarin) and diuretics are possible given dandelion's known pharmacological profile, though these have not been documented for isolated taraxasterol specifically. Pregnant and breastfeeding women should avoid isolated taraxasterol supplements due to a complete absence of safety data in these populations.